INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.
Inspire Medical Systems, Inc. (INSP) Q3 2024 Earnings Call Transcript
Inspire Medical Systems, Inc. (NYSE:INSP ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Ezgi Yagci – Vice President-Investor Relations Tim Herbert – President and Chief Executive Officer Rick Buchholz – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Danielle Antalffy – UBS Travis Steed – Bank of America Securities Adam Maeder – Piper Sandler David Rescott – Baird Michael Sarcone – Jefferies Richard Newitter – Truist Securities Larry Biegelsen – Wells Fargo Shagun Singh – RBC Kallum Titchmarsh – Morgan Stanley Jon Block – Stifel Anthony Petrone – Mizuho Americas Brett Fishbin – KeyBanc Capital Markets Chris Pasquale – Nephron Research Michael Polark – Wolfe Research Mike Kratky – Leerink Partners Suraj Kalia – Oppenheimer & Co Operator Good afternoon. My name is Dilem, and I'll be your conference operator today.
Here's What Key Metrics Tell Us About Inspire (INSP) Q3 Earnings
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inspire Medical Systems (INSP) Q3 Earnings and Revenues Surpass Estimates
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.29 per share a year ago.
Seeking Clues to Inspire (INSP) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Inspire (INSP) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
3 Medical Info Systems Stocks to Gain From Healthcare Digitization
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.
Inspire (INSP) Upgraded to Buy: What Does It Mean for the Stock?
Inspire (INSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Here's Why Inspire Medical Systems (INSP) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Inspire Medical Systems: Inspired, With Improving Risk-Reward (Rating Upgrade)
Inspire Medical Systems has shown impressive growth, become profitable and recently obtained FDA approval for a new device. The company's Inspire system treats sleep apnea with neurostimulation technology, achieving significant sales growth for years now. Trading at around 6 times sales, the company's strong performance, profitability, and growth potential make it an attractive investment.
Why Inspire Medical Systems (INSP) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Inspire (INSP) Might be Well Poised for a Surge
Inspire (INSP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
